Fisher Asset Management
EW icon

Fisher Asset Management’s Edwards Lifesciences EW Stock Holding History

Fisher Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.94M Sell
87,769
-44,430
-34% -$3.72M ﹤0.01% 436
2026
Q1 		$10.6M Sell
132,199
-13,446
-9% -$1.11M ﹤0.01% 393
2025
Q4 		$12.4M Sell
145,645
-101,775
-41% -$8.35M ﹤0.01% 382
2025
Q3 		$19.2M Sell
247,420
-68,972
-22% -$5.39M 0.01% 329
2025
Q2 		$24.7M Sell
316,392
-9,784,074
-97% -$730M 0.01% 292
2025
Q1 		$732M Buy
10,100,466
+325,190
+3% +$23.3M 0.32% 85
2024
Q4 		$724M Buy
9,775,276
+696,965
+8% +$48.8M 0.29% 78
2024
Q3 		$599M Buy
9,078,311
+806,705
+10% +$58.6M 0.25% 89
2024
Q2 		$764M Buy
8,271,606
+644,728
+8% +$57.1M 0.33% 79
2024
Q1 		$729M Buy
7,626,878
+498,599
+7% +$41.9M 0.34% 79
2023
Q4 		$544M Sell
7,128,279
-186,188
-3% -$13M 0.29% 90
2023
Q3 		$507M Sell
7,314,467
-703,324
-9% -$56.5M 0.29% 95
2023
Q2 		$756M Buy
8,017,791
+198,252
+3% +$17.2M 0.42% 73
2023
Q1 		$647M Buy
7,819,539
+146,921
+2% +$11.5M 0.39% 82
2022
Q4 		$572M Buy
7,672,618
+133,880
+2% +$10.3M 0.39% 80
2022
Q3 		$623M Buy
7,538,738
+208,057
+3% +$20M 0.47% 66
2022
Q2 		$697M Buy
7,330,681
+227,736
+3% +$23.6M 0.49% 63
2022
Q1 		$836M Buy
7,102,945
+320,643
+5% +$36M 0.49% 63
2021
Q4 		$879M Buy
6,782,302
+357,605
+6% +$41.7M 0.49% 52
2021
Q3 		$727M Buy
6,424,697
+267,356
+4% +$30.5M 0.45% 64
2021
Q2 		$638M Buy
6,157,341
+334,627
+6% +$31.5M 0.4% 66
2021
Q1 		$487M Buy
5,822,714
+244,081
+4% +$20.6M 0.34% 74
2020
Q4 		$509M Buy
5,578,633
+386,233
+7% +$32M 0.38% 67
2020
Q3 		$414M Buy
5,192,400
+204,982
+4% +$16M 0.36% 64
2020
Q2 		$345M Buy
4,987,418
+923,309
+23% +$65.6M 0.34% 71
2020
Q1 		$256M Buy
4,064,109
+4,040,349
+17,005% +$291M 0.32% 72
2019
Q4 		$1.85M Sell
23,760
-4,038
-15% -$315K ﹤0.01% 502
2019
Q3 		$2.04M Buy
27,798
+6,423
+30% +$451K ﹤0.01% 532
2019
Q2 		$1.32M Buy
+21,375
New +$1.29M ﹤0.01% 584

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Fisher Asset Management's EW Position: Q2 2026 in Review

Fisher Asset Management reduced its Edwards Lifesciences (EW) stake by 34% in Q2 2026, selling an estimated $3.72M and leaving 87,769 shares worth $7.94M. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Fisher Asset Management first reported a position in EW in Q2 2019 and has held it in 29 quarters since. The position peaked at $879M in Q4 2021. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Fisher Asset Management held 87,769 shares of Edwards Lifesciences worth $7.94M as of Q2 2026.
  • Fisher Asset Management sold 44,430 Edwards Lifesciences shares in Q2 2026, an estimated $3.72M.
  • Edwards Lifesciences made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #436 holding.
  • Fisher Asset Management first reported a position in Edwards Lifesciences in Q2 2019 and has held it in 29 quarters since.
  • Fisher Asset Management's Edwards Lifesciences position peaked at $879M in Q4 2021.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.